natgillin/translations-raw huggingface dataset:
A process for preparing cortexolone-17a-propionate in crystalline form I, wherein said crystalline form I is characterized by a DRX spectrum as represented in Figure 1 and by a DSC spectrum as represented in Figure 2 and by an IR spectrum as represented in Figure 3, said process comprising reacting a compound of Formula II: with a compound of Formula III R'OH (III) in the presence of a lipase from Candida, wherein R is CH3-CH2, and R' is a linear aliphatic chain containing 1-10 carbon atoms to give cortexolone-17a-propionate, and crystallizing said cortexolone-17a-propionate from tert-butylmethylether, to give cortexolone-17a-propionate in crystalline form I. 
Farmaceutski pripravak koji sadrži najmanje jedan kristalni oblik korteksolon-17a-propionata u vezi sa najmanje jednim fiziološki prihvatljivim ekscipijensom, gdje navedeni najmanje jedan kristalni oblik korteksolon-17a-propionata je odabran od: kristalnog oblika I okarakterizirano pomoću DRX kao što je prikazano na slici 1 i DSC kao što je prikazano na slici 2 i IR spektra kao što je prikazano na slici 3; kristalnog oblika III okarakterizirano pomoću DRX spektra kao što je prikazano na slici 7 ili 10 ili 13 i DSC spektra kao što je prikazano na slici 8 ili 11 ili 14 i IR spektra kao što je prikazano na slici 9 ili 12 ili 15; hidratnog kristalnog oblika IV okarakterizirano pomoću DRX spektra kao što je prikazano na slici 28.
Use of a compound of any one of Claims 1 to 14 for manufacture of a medicament for the treatment of a disease or medical condition in a mammal associated with mu opioid receptor activity. 
Uporaba spoja iz bilo kojeg od patentnih zahtjeva 1 do 14, naznačena time, da se ta uporaba odnosi na proizvodnju lijeka za liječenje bolesti ili medicinskog stanja u sisavaca povezanih s djelovanjem u opioidnog receptora.
The device of claim 1, wherein the first-layer pharmaceutical substance and the one or more additional pharmaceutical substances in the one or more additional layers are independently selected from the group consisting of L-triiodothyronine and L-thyroxine. 
Uređaj prema patentnom zahtjevu 1, naznačen time, što najmanje jedna od farmaceutske tvari prvog sloja i jedne ili više dodatnih farmaceutskih tvari jest ropinirol.
However, the latch sub shoulder and the latch keys limit the loads at which the jar mandrels and latch subs separate from one another. 
Ipak, element zasuna ramena i zasun sam ograničavaju opterećenja pri kojima se vreteno udaraca i clemcnt zasuna međusobno odvajaju.
The table illustrates the superior performance of the solubilized compound (1) formulations. 
Postupak za pripremu spoja (1), naznačen time što sadrži osiguranje intermedijera (2)
The invention can be applied to any of these versions of harvesting equipment. 
Izum se može primijeniti na bilo koju verziju žetelačke opreme.
The dredge tooth in accordance with anyone of claims 1-3, characterized in that the working section (23) has a generally trapezoidal transverse configuration perpendicular to the longitudinal axis (28). 
Potrošni dio u skladu s patentnim zahtjevom 4, naznačen time što radni dio (21) ima općenito trapezoidnu poprečnu konfiguraciju okomitu u odnosu na uzdužnu os (28).
9), wherein X35 is an amino acid residue corresponding to Aib, said amino acid residues of the sequence optionally including side chain protection; 
9) gdje X" je amino kiselinski ostatak odgovarajući za Aib, navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca;
Advantageously, said heterogeneous catalyst may according to one aspect of the present invention comprise said at least one surface area stabilizer in an effective amount up to 20% by weight, such as an effective amount up to 10% by weight, preferably said surface area stabilizers in an effective amount up to 7.5% by weight, such as surface stabilizers in an effective amount up to 5% by weight, and more preferably said surface stabilizers are present in an effective amount from 0.5-5% by weight, such as 1-3% by weight. 
Metoda u skladu s patentnim zahtjevom 33, pri čemu navedeni heterogeni katalizator obuhvaća navedeno barem jedno površinsko područje stabilizatora u učinkovitoj količini do 20 % prema težini, kao što je učinkovita količina do 10 % prema težini, poželjno je navedeno površinsko područje stabilizatora u učinkovitoj količimi do 7,5 % prema težini, kao što su površinski stabilizatori u učinkovitoj količini do 5 % prema težini, a još poželjnije su navedeni površinski stabilizatori prisutni u učinkovitoj količini od 0,5-5 % prema težini, kao što je 1-3 % prema težini.
obtaining rotational top end drive speed of the drill string during the time period; 
- dobivanja (53) vršne brzine vrtnje pogona navedene bušaće šipke (12) tijekom navedenog vremenskog perioda;
The container of the invention could also be fabricated by providing the thermo-sealable plastic bonding material to the exterior of the cup body 32 at the upper wall section 37 without departing from the scope of the present invention. 
Bilo koja od izvedbi spremnika može se također proizvoditi stavljanjem plastičnog materijala za spajanje, koji se može lijepiti kada je vruć, lokalno na vanjsku stranu tijela čaše kod gornjeg dijela stijenke 37, a da se ne odstupa od predmetnog izuma.
wherein Re is H or C1-4alkyl, and Rb is C1-4alkyl; or a pharmaceutically acceptable salt thereof. 
X o R pri čemu R* je H ili Crzalkil, a R" je Cyualkil; ili njegova farmaceutski prihvatljiva sol.
The present invention provides compounds which are serotonin reuptake inhibitors for the treatment of affective disorders, such as depression, anxiety disorders including general anxiety disorder, social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia. 
Ovaj izum nudi spojeve koji su inhibitori ponovne pohrane serotonina za liječenje afektivnih poremećaja, poput depresije, poremećaja tjeskobe uključujući poremećaj opća tjeskobe, poremećaja socijalne tjeskobe, poremećaja posttraumatskog stresa, opsesivno kompulzivnog poremećaja, poremećaja panike, napadaja panike, specifičnih fobija, socijalne fobije i agorafobije.
A method according to claim 1, wherein the inhibition of said protein is obtained by expressing in said plant of a silencing RNA targeting the gene encoding said protein. An expression cassette comprising: 
Metoda prema zahtjevu 1, naznačena time da se mhibicija spomenutog proteina postiže ekspresijom stišavajuće ribonukleinske kiseline u spomenutoj biljci, pri čemu se cilja na genetsko kodiranje spomenutog proteina.
Set the moulding funnel temperature at 70° C. Pump the formulated mass from mixing tank into the moulding funnel of the mogul machine. 
Postaviti temperaturu lijevka za kalupljenje na 70%C. Pumpati formuliranu masu iz rezervoara za miješanje u ljevak za kalupljenje mogul stroja za kalupljenje.
The pharmaceutical compositions mentioned above may also comprise an antibiotic as an active principle at a concentration of about 5-15 nM, preferably 10 nM. 
Spoj za uporabu kao u patentnom zahtjevu 10, koji također sadrži antibiotik kao aktivnu tvar u koncentraciji sadržanoj između 5-15 nM, preporučeno 10 nM.
provided that when is or then a is 1, wherein lower alkyl refers to a carbon chain composition of 1-4 carbon atoms. 
uz uvjet da kada [image] je [image] ili [image] tada a je 1, pri čemu se niži alkil odnosi na sastav ugljikovog prstena sa 1 do 4 atoma ugljika.
Thus for a typical adult patient, individual tablets or capsules are likely to contain from 1 to 10 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. 
Tako, za tipičnog odraslog pacijenta, individualne tablete ili kapsule će vjerojatno sadržavati od 1 do 10 mg aktivnog spoja u prikladnom farmaceutski prihvatljivom puniocu ili nosaču.
The dextran sulfate according to claim 1, wherein said Mn as measured by NMR spectroscopy is within an interval of 1850 and 2500 Da. 
Dekstran sulfat prema zahtjevu 1, naznačen time što je navedeni Mn kako je izmjeren NMR spektroskopijom unutar intervala od 1850 i 2500 Da.
A combination according to claim 3 wherein the B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija sukladno patentnim zahtjevima 3 ili 4, naznačena time, da je B2 agonist odabran iz skupine koji sadrži formoterol, salmeterol 1 OAB-149 opcionalno u obliku njihovih racemata, enantiomera, diastereomera 1 njihovih smjesa te opcionalno njihovih farmaceutski-kompatibilnih kiselinskih adicijskih soli.
The composition of claim 5, further comprising an anti-cancer agent, wherein the anti-cancer agent is optionally an antibody or a chemotherapeutic agent. 
Kompozicija patentnog zahtjeva 16, gdje antikancerogeni agens je antitijelo ili kemoterapijski agens.
fentanyl disposed in a mucoadhesive polymeric diffusion environment, wherein the mucoadhesive polymeric diffusion environment is a buffered environment having a pH between 6.5 and 8; and a barrier environment disposed relative to the mucoadhesive polymeric diffusion environment such that a unidirectional gradient is created upon application to the mucosal surface; 
buprenorfin odložen u mukoadhezivni polimerni difuzijski okoliš, pri čemu je mukoadhezivni polimerni difuzijski okoliš puferirani okološ koji ima pH između 4 i 6.5; i granični okoliš odložen u odnosu na mukoadhezivni polimerni difuzijski okoliš tako da se stvara jednosmjerni gradijent nakon primjene na površinu mukoze;
at least 11% of the cells in the population express on their surfaces detectable levels of CD289 (Toll-like receptor 9), 
(iv) najmanje 11 % stanica u populaciji na svojoj površini izražava uočljive razine CD289 (receptor 9 tipa Toll),
Rc, and Rd are independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or Rc, and Rd together with N atom to which they are attached may form a heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl; 
ili Ra i Rb zajedno s dušikom na koji su spojeni tvore pirolidinski, piperidinski, piperazinski, azetidinski, morpholinski ili tiomorfolinski prsten; ili Rb i RC zajedno s dušikom na koji su spojeni tvore pirolidinski, piperidinski, piperazinski, azetidinski, morpholinski ili tiomorfolinski prsten; i RC i Rd se neovisno biraju iz skupine koja se sastoji od H, alkila, supstituiranog alkila, cikloalkila, supstituiranog cikloalkila, arila, supstituiranog arila, heteroarila i supstituiranog heteroarila ili RC i Rd zajedno s atomom N na koji su spojeni tvore heterocikloalkil, supstituirani heterocikloalkil, heteroaril, ili supstituiran heteroaril;
SEM: standard error of the mean. 
Datum objave europske prijave patenta:
Process according to claim 1, further comprising the following steps for preparing compound (3): activation of 6-methyl-2-benzo[b]thiophenecarboxylic acid of formula (1) to the corresponding acyl chloride; 
Postupak prema patentnom zahtjevu 1, naznačen time da dalje obuhvaća sljedeće korake za pripravu spoja (3): a) aktivacija 6-metil-2-benzo[b]tiofenkarboksilne kiseline formule (1)
Then the corresponding moveable pressing members may be part of the first or annular member and the extension will form the second member. 
Tada mogu odgovarajući pomični tlačni elementi biti dio prvog ili prstenastog elementa i nije potreban nikakav drugi 1 odvojeni element.
The fibre sheath is, for example, made of fibres with a fineness of 1.0-3.3 dtex and a cut length of 35-60 mm. To form the sheath, the fibres form a bond but this does not impair the elastic stretch of the core filament. 
Omotač od vlakana je, na primjer, načinjen od vlakana s finoćom od 1,3-3,3 dtex i dužinu pojedinih komada 35-60 mm, Da bi se izradio taj omotač, vlakna su spojena, ali to ne slabi elastično istezanje središnje niti.
A method according to claim 13, wherein the magnetic plate (2) and the additional magnet (3, 3a, 3b) are arranged so as to produce a magnetic field having an angle of less than 45° to the plane of the said relief surface in at least one surface area not carrying a relief, engraving or cut-out. 
Postupak sukladno patentnom zahtjevu 13, naznačen time, da su magnetska ploča (2) i dodatni magnet (3, 34, 3b) postavljeni tako da stvaraju magnetsko polje s kutem manjim od 45 * u odnosu na ravninu navedene reljefne površine na najmanje jednom području površine bez reljefa, gravura ili ureza.
The binder according to claim 16, wherein the component having available aluminum is selected from the group consisting of Na2Al2O4, K2Al2O4, aluminum nitrate, aluminum acetate, aluminum chloride, aluminum formiate, and aluminum sulphate. The binder according to claim 10, wherein the admixture is selected from the group consisting of alkali salts, alkali silicates and alkali hydroxides, which increase a pH value of a solution and a reactivity of the C5S2$. 
Vezivo sukladno barem jednom od zahtjeva 3 do 8, naznačen time što sadrži litijeve soli i litijeve hidrokside i/ili druge alkalijske soli 1 alkalijske hidrokside 1 alkalijske silikate kao dodatak mješavini, pri čemu dodaci mješavini poput alkalijskih soli i alkalijskih hidroksida i alkalijskih silikata, koji povećavaju PH vrijednost otopine i stoga 1 reaktivnost C5S2$, su posebno poželjni.
A compound according to claim 1, selected from the following compound and pharmaceutically acceptable salts, solvates, and hydrate thereof: 
Pripravak u skladu sa zahtjevom 1, naznačen time, da: spoj je izabran među slijedećim spojem 1 njegovim Farmaceutski prihvatljivim solima, solvatima i hidratima:
The compound according to claim 1 for use as in claim 1, wherein said compound has formula (VII): 
Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (VII): (Ri £
The genetically modified cell of any of embodiments 1 to 8, wherein the cell is a stem cell. The genetically modified cell of embodiment 9, wherein the stem cell is a hematopoietic stem cell. 
Genetski modificirana stanica prema patentnom zahtjevu 1, pri čemu je stanica matična stanica, opcionalno pri čemu je matična stanica hematopoetska matična stanica kao što je CD34+ hematopoetska matična stanica.
A method of preparing a compound, salt, or solvate of the formula: comprising 
Postupak dobivanja spoja, soli ili solvata formule HR P20121020 T1
The fan assembly of claim 1, wherein the nozzle comprises a surface located adjacent the mouth and over which the mouth is arranged to direct the air flow. 
Ventilatorski sustav prema bilo kojem od prethodnih zahtjeva, gdje naglavak (14) obuhvaća površinu (28) smještenu uz usta (26) i preko koje su usta (26) smještena da usmjeravaju struju zraka.
Add the sorbitol liquid (non-crystallizing), acacia (spray dried) and xylitol. 
Dodati tekući sorbitol (ne-kristalizirajući), akaciju (osušenu raspršivanjem) i ksilitol.
Cy1 is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; 
Cy1 je dabran od supstituiranog ili nesupstituiranog cikloalkila, supstituirane ili nesupstituirane heterociklične skupine, supstituiranog ili nesupstituiranog arila i supstituiranog ili nesupstituiranog heteroarila;
Preferably, said concentration is within a range of about 1.5% to about 2.5% sodium hydroxide. 
Poželjno je da raspon koncentracije bude od 1.5% pa do 2.5%.
represents alkylaryl, arylalkyl, carboxy, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, cycloalkenyl, carbamoyl, hydroxyalkyl, aryloxy, alkoxycarbonyloxy, alkoxycarbonyl, alkoxy, alkoxyalkyl, aryl, a heterocyclic ring, aminocarbonyl, alkylthio, alkylcarbonylamino, hydroxy, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, or amino, all of which are optionally substituted by one or more, same or different substituents selected from R8, or R12 represents hydrogen; 
predstavlja alkilaril, arilalkil, karboksi, alkil, alkenil, alkinil, haloalkil, cikloalkil, cikloalkenil, karbamoil, hidroksialkil, ariloksi, alkoksikarboniloksi, alkoksikarbonil, alkoksi, alkoksialkil, aril, heterociklični prsten, aminokarbonil, alkiltio, alkilkarbonilamino, hidroksi, alkilkarbonil, arilkarbonil, alkilkarboniloksi ili amino, gdje su svi oni izborno supsitituirani sa jednim ili više, istih ili različitih supstituenata izabranih od R8, ili R12 predstavlja vodik;
[Paragraph 2] The compound of paragraph 1 wherein R1 is independently selected from the group consisting of chloro, fluoro, and bromo; 
R, je neovisno odabrana iz skupine koju čine kloro, fluoro, i bromo; 1 X je odabrana iz skupine koju čine
extracting chloroplastic DNA from seeds; and 
(a) ekstrakcije DNA kloroplasta iz sjemena; 1
In particular, the efficacy of rifamycin SV was verified by means of an evaluation of the MIC (Minimum Inhibiting Concentration) on specific pathogenic bacterial strains, such as, for example, Escherichia coli, Enterobacter faecalis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella typhi and Enterobacter cloacae as shown in the following Table A. 
Posebno je uspješnost rifamicina SV određena određivanjem minimalne inhibitorne koncentracije (MIC) na specifičnim patogenim bakterijskim sojevima kao što su na primjer Escherichia coli, Enterobacter faecalis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella typhi 1 Enterobacter cloacae, kao što je prikazano u slijedećoj Tablica A. HR P20080252 T3
Such a dispenser and container are described in detail in NL 1019054 and in WO 00/039 44 A1, both in the name of the Applicant. 
Takav djelitelj i spremnik su pobliže opisani u NL 1019054 i u WO 00/039 44 A1, oba u ime Kandidata.
an optional dryer, disposed in operable communication with the material feed system, configured to remove moisture contained within a carbon-containing feedstock; 
sušenje navedene sirovine radi uklanjanja barem dijela vlage koja se nalazi unutar navedene sirovine;
XRPD patterns of the hydrogen adipate, hydrogen malonate, L-lactate, hydrogen fumarate, hydrogen succinate, benzene sulfonate, hydrogen maleate and salicylate salts are shown in Figures 1-8 and characteristic main peaks are listed in Table 1 below. 
Sol spoja formule [1] sol koja je odabrana između soli vodikovog adipata, vodikove malonatne soli, vodikove fumaratne soli, vodikove sukcinatne soli, benzen-sulfonatne soli, vodikove maleatne soli i salicilatne soli spoja formule [1].
The autonomous equipped underwater vehicle (100) according to claim 6, wherein said scalar magnetometers (12) forming said magnetic gradiometer (4) effect measurements of the magnetic field with an accuracy of up to 0.01 nT. 
Autonomno opremljeno podvodno vozilo (100) sukladno Zahtjevu 6, pri čemu navedeni skalarni magnetometri (12) koji formiraju navedeni magnetski gradiometar (4) vrše mjerenja magnetskog polja s točnošću do 0.01 nT.
Use of (a) a compound of the formula [I] of claim 24 or a pharmaceutically acceptable salt thereof as an active ingredient, which is used in combination with (b) at least one other antitumor compound, for the production of an antitumor agent. 
Upotreba (a) spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, kao aktivni sastojak, kojeg se upotrebljava u kombinaciji s (b) najmanje još jednim antitumorskim spojem, naznačena time što su spoj formule [1] i dodatni antitumorski spoj namijenjeni proizvodnji antitumorskog sredstva.
The process of claim 2, the process comprising providing the pre-lyophilization mixture wherein the organic solvent is in the range from 3% to 15%. 
Postupak prema zahtjevu 1, postupak obuhvaća primjenu pre-liofilizacijske smjese gdje je organsko otapalo u rasponu od 3% do 15%.
The method of claim 1, wherein the compound of Formula Ia is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da ima strukturu izabranu iz skupine koja se sastoji od:
A pharmaceutical composition according to any one of paras. 1 to 18, wherein, if arginine is present, the molar ratio of arginine to said HDAC inhibitor is from 0.5 to 5. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, naznačen time, da je molarni odnos arginina prema spomenutom HDAC inhibiloru najmanje 0,5 do 5.
The pharmaceutical composition of Claim 3, wherein the polymorph of Formula I is present in at least 95% of the total weight, and wherein the pharmaceutical composition is in a solid dosage form. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u najmanje 95% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
each X represents independently a nitrogen, a carbon carrying a hydrogen, a carbon carrying a chlorine group or a carbon carrying a cyano group; and Z is a functional group capable of reaction with a matrix selected from amine, azide and hydroxyl or is an amine of amine-activated agarose that reacts directly with the ligand; for the production of purified IL-18 binding protein (IL-18BP). 
Z je funkcionalna skupina koja može reagirati sa matricom odabranom od amina, azida i hidroksila ili je amin iz amin-aktivirano agaroze koji reagira izravno sa ligandom, za dobivanje pročišćenog IL-18 vezujućeg proteina (IL-18BP). Uporaba prema zahtjevu 1, naznačena time da A; i A, su amin sa strukturom Ik =-N->B.
The method of claim 1, wherein the therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof is administered up to three times or more a day for as long as the subject is in need of treatment for the proliferative disorder. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje tri ili više puta dnevno sve dok je subjektu potrebno liječenje akutne mijeloične leukemije (AML).
The method of claim 13 or 14, wherein the treatment agent is a nodulariser. 
Postupak prema zahtjevu 13 ili 14, pri čemu je agens za preradu nođulizator.
a determining section configured to determine an amount of resource of the control information for each of the plurality of layers by multiplying a reciprocal of a total number of transmittable bits per resource element for all of the plurality of layers with a number of bits of the control information and with an offset amount; and a transmission section configured to transmit the control information using the determined amount of resource of the control information, wherein 
sekciju određivanja (204) koja određuje količinu resursa kontrolne informacije u pluralitetu slojeva; i sekciju prijenosa (206) koja prenosi kontrolnu informaciju na temelju količine resursa kontrolne informacije, naznačeno time da je količina resursa QCW#0+CW#1 kontrolne informacije određena jednadžbom 1:
Process for preparing the crystalline rosuvastatin calcium trihydrate according to any one of claims 1 to 5, which process comprises crystallizing rosuvastatin calcium from a solution in water or a mixture of water with an organic solvent, particularly in a ratio of 0.05:1 to 1:0.05 (v:v), more preferably 0.1:1 to 1:0.1, most preferably 0.5:1 to 1:0.5. 
Postupak prema zahtjevu 9, naznačen time, da se reakcija provodi u mješavini organskog otapala i vode, posebno u omjeru od 10:1 do 1:10, poželjno od 8:1 do 1:3, još bolje od 5:1 do 1:1, najbolje od 4:1 do 2:1, pri čemu je organsko otapalo poželjno odabrano od acetonitrila, acetona, metanola, etanola, izopropanola i njihovih mješavina.
Process of claims 18 or 19, wherein in a third step of step a2) the alcohol ester of formula XXI wherein R5 is benzyl is formed with a benzyl halogenide or a benzyl sulfonylester in a polar aprotic solvent at a reaction temperature from 20°C to 120°C. 
Postupak prema patentnom zahtjevu 18 ili 19, naznačen time, da se u trećem koraku od koraka a2), alkoholni ester formule XXI gdje je R5 benzil, tvori s benzil halogenidom ili benzil sulfonilesterom u polarnom aprotičnom otapalu, na temperaturi reakcije od 20 °C do 120 °C.